London, July 10, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for iOnctura and is pleased to announce the placement of Steven Sciuto as Chief Financial Officer.iOnctura is a clinical-stage precision oncology company combating neglected and hard-to-treat cancers with a pipeline of first-in-class small molecules.Steven Sciuto is a seasoned finance executive with more than 15 years of corporate finance leadership and capital markets experience within…
Read July eNews here 👉 https://shorturl.at/OHhJc
Featuring:
✅ A Sense of Togetherness to Succeed in Tough Times by Tony Jones, CEO, One Nucleus
✅ Unlocking Strategic Procurement in Life Sciences, 18 June 2025 by Alicia Gailliez, Business Development Manager, One Nucleus
✅ Will London, 3 December 2025, be the Genesis of Your Next Step to Success? by Tony Jones, One Nucleus
✅ Targeting the Right Investors at the Right Time with the Right Proposition – How One Nucleus Can Support Members on the Fundraising Trail by Tony Jones, One Nucleus
✅ Bridging the Knowledge Gap: Why Training Your Team on…
London & Copenhagen, July 8, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Biomia and is pleased to announce the placement of Frederick Westhorpe, PhD as Chief Scientific Officer (CSO).Biomia is a preclinical biotech company that uses synthetic biology, biomanufacturing, and AI to discover and optimize nature-inspired medicines. The Company develops novel treatments for CNS disorders like cognitive deficits in mental health, neurodegenerative…
At the forefront of immunotherapy innovation, Creative Biolabs boasts a next-generation custom CAR design and construction platform that allows researchers to create highly specific chimeric antigen receptors for various targets and applications. From streamlining signal domains to selecting best-fit backbones for vectors, their platform is designed for flexibility, precision, and velocity. Creative Biolabs leads in hybrid CAR engineering through the design of multi-functional receptor structures that enhance antigen recognition, modulate activation thresholds, and introduce dual-…
LONDON, UK and BRUSSELS, Belgium - July 3, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed search assignments for Augustine Therapeutics NV (“Augustine”) and is pleased to announce the placements of Carl Bjartmar as Chief Medical Officer (CMO), Virginie Cartage as Chief Financial Officer (CFO), and Rie Schultz Hansen as Chief Scientific Officer (CSO).Augustine Therapeutics is a biotechnology company focused on developing new therapies for neuromuscular,…
Timely access to high-quality peptides is essential in drug discovery, especially for screening, structure-activity relationship (SAR) studies, and early-stage preclinical research. Any delay in peptide synthesis can slow down critical experiments, affect project timelines, and limit the ability to make rapid decisions in lead optimisation.Recognising the critical role of fast, reliable, and risk-free peptide delivery in accelerating the development of new therapies, launched the o2h Peptide Guarantee Programme, designed to deliver peptides in just 2 weeks, to accelerate your discovery…
– Reassure Pregnancy is being used to monitor signs of pre-eclampsia in two NHS hospitals –
– Camgenium is pioneering the development of software to ensure high-quality antenatal care is accessible to all women –
Thursday 26th June 2025, Cambridge, UK – Camgenium, a leading medical device software company, has announced that its software product, ‘Reassure Pregnancy’, can improve outcomes for pregnant women at risk of pre-eclampsia through at-home monitoring. The Reassure Pregnancy system allows women to proactively monitor their symptoms at home using a simple app. Data is shared in real…
Cancer Research Horizons, the innovation arm of Cancer Research UK, has appointed its first Clinical Advisory Board to provide strategic guidance on the development of novel cancer therapeutics emerging from its drug discovery division, Therapeutic Innovation.
The Clinical Advisory Board brings together world-leading oncologists with expertise in early-phase clinical trials. The board will assess the clinical positioning and utility of drug discovery projects, ensuring that medical need and patient impact are central to decision-making from the earliest stages of target selection.
The…
Devens, MA, USA — Veranova is pleased to announce the appointment of Dr. Matteo Villain as Vice President of Peptides and Oligonucleotides. Dr. Villain will bring extensive expertise in peptide and oligonucleotide development and manufacturing to Veranova as the company continues to strengthen its position as a key player in the Peptide and Oligonucleotide (TIDES) space.
“Dr. Villain, and his holistic experience in the development and manufacturing of peptide APIs, will be a tremendous asset to Veranova,” says Rohtash Kumar, Senior Vice President of Development Operations and Chief…
Amsbio, in association with Nordmark Biochemicals, has expanded its range of Collagenase and Neutral Protease NB enzymes with GMP grade formats and protocols to support advanced tissue dissociation workflows for applications from research to clinical use.
These enzymes, derived from Clostridium histolyticum, are critical raw materials for isolating viable cells from complex tissues - an essential step in tissue engineering, cell therapy and regenerative medicine. Their clinical relevance is reinforced by recent studies to set up a protocol for isolation, manufacturing, and…